Navigation Links
Life Technologies Announces Second Quarter 2011 Results
Date:7/28/2011

CARLSBAD, Calif., July 28, 2011 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced results for its second quarter ending June 30, 2011. Non-GAAP revenue for the second quarter was $945 million, an increase of 4 percent over the $906 million reported for the second quarter of 2010. Excluding the impact of currency, revenue growth for the quarter was 3 percent compared to the same period prior year.

(Logo:  http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

"Our second quarter results were lower than anticipated, the result of continued budget pressure on academic and government funded research in the US and Europe, the lingering effects of the Japan earthquake on the 5500 launch, and a temporary slowdown in our China business resulting from the evolution of our commercial strategy," said Gregory T. Lucier, Chairman and Chief Executive Officer of Life Technologies.  "That said, we are taking concerted actions to address these challenges and are expecting growth to increase in the second half of the year.  To offset the pressures on life science industry funding, which we expect to continue for the remainder of the year, we are accelerating a number of cost savings initiatives which will create a much leaner organization by the end of 2011.  We have made good progress on the 5500 launch and continue to gain significant traction with our Ion Torrent products. And finally, the third quarter marks our return to higher growth in China and the payoff from our change in strategy there. We expect our growth in the region to return to historic levels over the next several quarters."

Share Repurchase ProgramThe company announced a $200 million share repurchase program, which supplements an existing authorization. In total, the company now has authorization to repurchase up to $500 million in shares on the open market, subject to market conditions and other factors.

Analysis of Second Quarter 2011 Results

  • Second quarter non-GAAP 2011 revenue increased 4 percent over the previous year.  Revenue growth without the impact from currency was 3 percent.
  • Non-GAAP gross margin in the second quarter was 64.2 percent, 350 basis points lower than the same period prior year due to the negative impact from mix and currency partially offset by the positive impact from price. The negative impact from mix was primarily due to increased sales of the 5500 Genetic Analyzer upgrade. The launch of the 5500 was delayed due to the earthquake in Japan, resulting in a high number of upgrades shipped in the second quarter.
  • Non-GAAP operating margin was 27.8 percent in the second quarter, 230 basis points lower than the same period prior year, primarily due to lower sales and gross margins partially offset by lower operating expenses.
  • Second quarter non-GAAP tax rate was 27.9 percent.
  • Diluted weighted shares outstanding were 184.8 million in the second quarter.
  • Cash flow from operating activities for the second quarter was $204 million.  Second quarter capital expenditures were $17 million and resulting free cash flow was $187 million. The company ended the quarter with $565 million in cash and short-term investments.
  • The following analysis of diluted earnings per share identifies specific items that affect the comparability of results between periods. Reconciliations between the company's GAAP and non-GAAP results for the periods reported are presented in the attached tables and on the company's Investor Relations page at www.lifetechnologies.com.

  • Three Months Ending Jun 3020112010%GAAP earnings per share

    $0.52

    $0.58

    (10%)Non-cash interest expense (FSP APB14-1)

    0.03

    0.03Business integration and other charges

    0.08

    0.09Amortization of acquisition related expenses

    0.26

    0.21Non-GAAP earnings per share$0.89$0.91(2%)Business Highlights:

  • Cell Systems division non-GAAP revenue was $243 million in the second quarter, an increase of 5 percent over the same period last year.  Excluding the impact from currency, organic revenue grew 4 percent year over year.  Mid teens growth in the BioProduction business was tempered by slower growth in other product areas, which were negatively impacted by continued funding pressures in the US and Europe, and the temporary slowdown in China.
  • Molecular Biology Systems division non-GAAP revenue was $432 million, a decline of less than 1 percent over prior year.  Excluding the impact from currency, organic revenue for the division declined 2 percent.  Strong sales of qPCR consumables and molecular testing kits sold into applied markets were offset by slower growth in government funded accounts in the US and Europe as well as the temporary slowdown in China.
  • Genetic Systems division non-GAAP revenue was $265 million in the second quarter, an increase of 12 percent over the same period last year.  Excluding the impact from currency, revenue increased 11 percent.  Strong sales of the Ion Torrent PGM™ and the 5500 Series Genetic Sequencer were partially offset by reduced demand for CE instruments, the result of continued funding pressures in government funded accounts, as well as lower sales of next generation sequencing consumables as the 5500 ramps up.
  • Regional revenue growth rates for the quarter compared to the same quarter of the prior year were as follows: the Americas grew 3 percent, Europe 2 percent, Asia Pacific 3 percent and Japan grew 8 percent.
  • The company called and settled $350 million of 3.25% Convertible Senior Notes due 2025.  

  • Financial Outlook:  Comments are subject to the risk factors detailed in the Safe Harbor Statement section of this release. Looking ahead to the second half of 2011, the company expects constant currency revenue growth to be between 3 and 5 percent. The acceleration in total company revenue growth rate from the first half of 2011 is expected to result from an increase in revenue growth in China, and continued strong growth in sales of the Ion Torrent PGM.

    Resulting fiscal year 2011 constant currency revenue growth is expected to be between 2 and 4 percent. This level of revenue growth is expected to result in approximately $3.70 to $3.80 of non-GAAP earnings per share.

    Constant currency revenue growth for fiscal year 2012 is expected to be in the mid-single digits. This level of revenue growth is expected to result in double digit earnings growth.

    The company will provide further detail on its business outlook during the webcast today.

    Webcast Details The company will discuss its financial and business results as well as its business outlook on its webcast at 8:00 AM ET today.  This webcast will contain forward-looking information.  The webcast will include a discussion of "non-GAAP financial measures" as that term is defined in Regulation G.  For actual results, the most directly comparable GAAP financial measures and information reconciling these non-GAAP financial measures to the company's financial results determined in accordance with GAAP, as well as other material financial and statistical information to be discussed on the webcast will be posted at the company's Investor Relations Web site at www.lifetechnologies.com. The webcast can be accessed through the investor relations page of the Life Technologies' website at http://ir.lifetechnologies.com/events.cfm. A replay of the webcast will be available on the company's website through Thursday, August 18, 2011.

    About Life Technologies Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, GIBCO, Ambion, Molecular Probes and Taqman products.  Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 3,900 patents and exclusive licenses. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com.

    Safe Harbor Statement Certain statements contained in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and Life Technologies intend that such forward-looking statements be subject to the safe harbor created thereby.  Forward-looking statements may be identified by words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "will," or words of similar meaning and include, but are not limited to, statements about the expected future business and financial performance of  the company. Such forward-looking statements include, but are not limited to, statements relating to financial projections, including revenue and pro forma EPS projections; success of acquired businesses, including cost and revenue synergies; development and increased flow of new products; leveraging technology and personnel; advanced opportunities and efficiencies; opportunities for growth; expectations of prospective new standards, new delivery platforms, and new selling specialization and effectiveness; and corporate strategy and performance.  A number of the matters discussed in this press release and presentation that are not historical or current facts deal with potential future circumstances and developments, including future research and development plans. The discussion of such matters is qualified by the inherent risks and uncertainties surrounding future expectations generally and other factors that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to:  volatility of the financial markets; and the risks that are described from time to time in Life Technologies' reports filed with the SEC.  This press release and presentation speaks only as of its date, and the company disclaims any duty to update the information herein.

    Non-GAAP Measurements

    This press release includes certain financial information which constitutes "non-GAAP financial measures" as defined by the SEC.  The GAAP measures which are most directly comparable to these measures, as well as a reconciliation of these measures with the most directly comparable GAAP measures, can be found at on the Investor Relations portion of the company's website at www.lifetechnologies.com.

    Investor and Financial Contacts:
    Eileen Pattinson
    Investor Relations
    (760) 603-7208

    LIFE TECHNOLOGIES CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONSAND RECONCILIATION OF NON-GAAP ADJUSTMENTS(1)For the three monthsFor the three months(in thousands, except per share data)

    ended June 30, 2011ended June 30, 2010(unaudited)GAAPAdjustmentsNon-GAAPGAAPAdjustmentsNon-GAAPRevenues$
    941,135

    $
    3,638

    (2)

    $
    944,773$
    903,732

    $
    ,786

    (2)

    $
    905,518Cost of revenues

    340,075

    (2,094)

    (3)

    337,981293,000

    (313)

    (3)

    292,687Purchased intangibles amortization

    76,476

    (76,476)

    (4)-70,051

    (70,051)

    (4)

    -Gross profit

    524,584

    82,208606,792540,681

    72,150612,831Gross margin

    55.7%64.2%59.8%67.7%Operating expenses:Selling, general and administrative

    254,764

    (1,452)

    (5)

    253,312252,813

    (1,914)

    (5)

    250,899Research and development

    91,085

    (469)

    (5)

    90,61690,344

    (684)

    (5)

    89,660Purchased in-process research and development

    -

    --1,650

    (1,650)

    (4)

    -Business consolidation costs

    18,666

    (18,666)

    (6)-23,446

    (23,446)

    (6)

    -Total operating expenses

    364,515

    (20,587)343,928368,253

    (27,694)340,559Operating income

    160,069

    102,795262,864172,428

    99,844272,272Operating margin

    17.0%27.8%19.1%30.1%Interest income

    1,153

    -1,1531,105

    -1,105Interest expense

    (42,774)

    8,833

    (7)

    (33,941)(39,309)

    11,337

    (7)

    (27,972)Loss on divestiture of equity investments

    -

    --(7,876)

    7,876

    (8)

    -Other income (expense), net

    (3,589)-(3,589)2,019-2,019Total other income (expense), net

    (45,210)

    8,833(36,377)(44,061)

    19,213(24,848)Income from operations before provision for income taxes

    114,859

    111,628226,487128,367

    119,057247,424Income tax provision

    (19,646)

    (43,434)

    (9)

    (63,080)(17,826)

    (55,068)

    (9)

    (72,894)Net income

    95,213

    68,194163,407110,541

    63,989174,530Net loss attributable to non-controlling interests

    253

    (105)

    (10)

    14827-27Net income attributable to controlling interest$
    95,466$
    8,089$
    3,555$
    ,568$
    3,989$
    74,557Effective tax rate

    17.1%27.9%13.9%29.5%Add back interest expense for subordinateddebt, net of tax

    33335050Numerator for diluted earnings  per share$
    95,499

    $
    8,089
    $
    3,588
    $
    ,618

    $
    3,989
    $
    74,607
    Earnings per common share:Basic earnings per share attributable to controlling interest

    $
    .53
    $
    .91
    $
    .61
    $
    .96
    Diluted earnings per share attributable to controlling interest

    $
    .52
    $
    .89
    $
    .58
    $
    .91
    Weighted average shares used in per share calculation:Basic179,031179,031182,484182,484Diluted184,761184,761191,084191,084(1)  The Company reports Non-GAAP results, which excludes business consolidation costs, amortization of purchase accounting adjustments to deferred revenue, fair market value adjustments to contingent consideration liabilities, charges for inventory revaluation, amortization of acquired intangibles and depreciation of acquired property, plant, and equipment to provide a supplemental comparison of the results of operations.  In addition, charges related to non-cash interest expense incurred as a result of the retrospective application of the bifurcation requirement between equity and debt prescribed by the Financial Accounting Standards Board Accounting Standards Codification, or ASC, Topic of Debt with Conversion and Other Options, charges associated with discontinued products, and the impact from the divestiture of our joint venture have been excluded from Non-GAAP results.   (2)  Add back revenue related to returns of a discontinued product of $2.8 million and fair value amortization of purchased deferred revenue of $0.8 million for the three months ended June 30, 2011. Add back fair value amortization of purchased deferred revenue of $1.8 million for the three months ended June 30, 2010.   (3)  Add back charges for inventory reserves related to a discontinued product of $2.1 million for the three months ended June 30, 2011 and add back noncash charges for purchase accounting inventory revaluations of $0.3 million for the three months ended June 30, 2010.   (4)  Add back amortization of purchased intangibles and write off of purchased in-process research and development.(5)  Add back depreciation of purchase accounting property, plant, and equipment revaluations.   (6)  Add back business consolidation costs.   (7)  Add back charges related to non-cash interest expense as a result of the provision adopted in accordance with the ASC Topic of Debt with Conversion and Other Options of $7.3 million and $11.3 million for the three months ended June 30, 2011 and 2010, respectively. Adjust for imputed finance charge of $1.5 million associated with contingent consideration on business acquisitions for the three months ended June 30, 2011.   (8)  Adjust for loss on divestiture of equity investments.   (9)  Non-GAAP tax differs from GAAP tax expense primarily because certain acquisition related costs such as restructuring, amortization of acquired intangibles, depreciation of acquired property, plant, and equipment, and fair market value adjustments to contingent consideration liabilities associated with certain acquisitions, and charges associated with discontinued products.  In addition, GAAP net income includes interest expense with related income tax benefits as a result of the provision adopted in accordance with the ASC Topic of Debt with Conversion and Other Options but excluded for Non-GAAP purposes. These deductions produce a GAAP only tax benefit which is added back for Non-GAAP presentation.(10)  Add back noncash charges for purchase accounting inventory revaluations and depreciation of purchase accounting property, plant and equipment revaluations attributable to non-controlling interest, net of tax benefit.   LIFE TECHNOLOGIES CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONSAND RECONCILIATION OF NON-GAAP ADJUSTMENTS(1)For the six monthsFor the six months(in thousands, except per share data)

    ended June 30, 2011ended June 30, 2010(unaudited)GAAPAdjustmentsNon-GAAPGAAPAdjustmentsNon-GAAPRevenues 

    $
    ,837,029

    $
    4,567

    (2)

    $
    ,841,596$
    ,788,675

    $
    3,877

    (2)

    $
    ,792,552Cost of revenues

    640,778

    (722)

    (3)

    640,056574,754

    (522)

    (3)

    574,232Purchased intangibles amortization

    152,627

    (152,627)

    (4)-140,137

    (140,137)

    (4)-Gross profit

    1,043,624

    157,9161,201,5401,073,784

    144,5361,218,320Gross margin

    56.8%65.2%60.0%68.0%Operating expenses:Selling, general and administrative

    507,606

    (3,740)

    (5)

    503,866512,499

    (3,864)

    (5)

    508,635Research and development

    183,859

    (1,779)

    (5)

    182,080176,697

    (1,332)

    (5)

    175,365Purchased in-process research and development

    -

    --1,650

    (1,650)

    (4)

    -Business consolidation costs

    33,349

    (33,349)

    (6)-48,712

    (48,712)

    (6)-Total operating expenses

    724,814

    (38,868)685,946739,558

    (55,558)684,000Operating income

    318,810

    196,784515,594334,226

    200,094534,320Operating margin

    17.4%28.0%18.7%29.8%Interest income

    2,040

    -2,0402,452

    -2,452Interest expense

    (85,919)

    17,558

    (7)

    (68,361)(80,827)

    22,491

    (7)

    (58,336)Loss on early retirement of debt

    -

    --(54,185)

    54,185

    (8)

    -Gain on divestiture of equity investments

    -

    --37,260

    (37,260)

    (9)

    -Other income (expense), net

    (4,941)-(4,941)(1,977)

    6,463

    (10)

    4,486Total other income (expense), net

    (88,820)

    17,558(71,262)(97,277)

    45,879(51,398)Income from operations before provision for income taxes

    229,990

    214,342444,332236,949

    245,973482,922Income tax provision

    (41,198)

    (81,999)

    (11)

    (123,197)(34,902)

    (108,544)

    (11)

    (143,446)Net income

    188,792

    132,343321,135202,047

    137,429339,476Net loss attributable to non-controlling interests

    361

    (203)

    (12)

    15827-27Net income attributable to controlling interest$
    89,153$
    32,140$
    321,293$
    202,074$
    37,429$
    339,503Effective tax rate

    17.9%27.7%14.7%29.7%Add back interest expense for subordinateddebt, net of tax

    6666101101Numerator for diluted earnings  per share$
    89,219

    $
    32,140
    $
    321,359
    $
    202,175

    $
    37,429
    $
    339,604
    Earnings per common share:Basic earnings per share attributable to controlling interest

    $
    .05
    $
    .79
    $
    .11
    $
    .87
    Diluted earnings per share attributable to controlling interest

    $
    .02
    $
    .73
    $
    .06
    $
    .78
    Weighted average shares used in per share calculation:Basic 

    179,698179,698181,675181,675Diluted

    185,513185,513190,459190,459(1)  The Company reports Non-GAAP results, which excludes business consolidation costs, amortization of purchase accounting adjustments to deferred revenue, fair market value adjustments to contingent consideration liabilities, charges for inventory revaluation, amortization of acquired intangibles and depreciation of acquired property, plant, and equipment to provide a supplemental comparison of the results of operations.  In addition, charges related to non-cash interest expense incurred as a result of the retrospective application of the bifurcation requirement between equity and debt prescribed by the Financial Accounting Standards Board Accounting Standards Codification, or ASC, Topic of Debt with Conversion and Other Options, costs associated with the early termination of outstanding indebtedness, charges associated with discontinued products and the impact from the divestiture of our joint venture have been excluded from Non-GAAP results.   (2)  Add back revenue related to returns of a discontinued product of $2.8 million and fair value amortization of purchased deferred revenue of $1.7 million for the six months ended June 30, 2011. Add back fair value amortization of purchased deferred revenue of $3.9 million for the six months ended June 30, 2010.   (3)  Add back charges for inventory reserves related to a discontinued product of $2.1 million and $0.5 million of purchase accounting related cost of revenue revaluation, offset by contingent consideration revaluation of $1.9 million for the six months ended June 30, 2011.  Add back noncash charges for purchase accounting inventory revaluations of $0.5 million for the six months ended June 30, 2010.   (4)  Add back amortization of purchased intangibles and write off of purchased in-process research and development.(5)  Add back depreciation of purchase accounting property, plant, and equipment revaluations.   (6)  Add back business consolidation costs.   (7)  Add back charges related to non-cash interest expense as a result of the provision adopted in accordance with the ASC Topic of Debt with Conversion and Other Options of $14.5 million and $22.5 million for the six months ended June 30, 2011 and 2010, respectively. Adjust for imputed finance charge of $3.1 million associated with contingent consideration on business acquisitions for the six months ended June 30, 2011.   (8)  Add back loss on early retirement of debt.   (9)  Adjust for gain on divestiture of equity investments.   (10)  Adjust for gain on impaired security recovery of $6.7 million and gain on foreign currency related to joint venture divestiture of $1.0 million offset by loss on discontinuance of cash flow hedge of $12.9 million and joint venture purchase accounting adjustment of $1.2 million for the six months ended June 30, 2010.(11)  Non-GAAP tax differs from GAAP tax expense primarily because certain acquisition related costs such as restructuring, amortization of acquired intangibles, depreciation of acquired property, plant, and equipment, and fair market value adjustments to contingent consideration liabilities associated with certain acquisitions and charges associated with discontinued products.  In addition, GAAP net income includes interest expense with related income tax benefits as a result of the provision adopted in accordance with the ASC Topic of Debt with Conversion and Other Options but excluded for Non-GAAP purposes. These deductions produce a GAAP only tax benefit which is added back for Non-GAAP presentation.(12)  Add back noncash charges for purchase accounting inventory revaluations and depreciation of purchase accounting property, plant and equipment revaluations attributable to non-controlling interest, net of tax benefit.   LIFE TECHNOLOGIES CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSFor the six monthsended June 30,(in thousands)(unaudited)

    20112010Net income$
    88,792$
    202,047Add back amortization and share-based compensation

    200,391188,294Add back depreciation

    60,36661,005Balance sheet changes

    (103,168)(100,566)Other noncash adjustments

    (26,842)(51,441)Net cash provided by operating activities

    319,539299,339Capital expenditures

    (33,799)(55,513)Free cash flow285,740243,826Net cash provided by (used in) investing activities

    (50,101)267,627Net cash used in financing activities

    (543,721)(421,559)Effect of exchange rate changes on cash

    14,641(15,202)Net increase (decrease) in cash and cash equivalents$
    (293,441)
    $
    74,692
    LIFE TECHNOLOGIES CORPORATIONCONDENSED CONSOLIDATED BALANCE SHEETSJune 30, December 31, (in thousands)

    20112010ASSETS (unaudited) Current assets:Cash and short-term investments

    $
    565,099$
    854,801Trade accounts receivable, net of allowance for doubtful accounts

    663,176587,456Inventories

    367,721323,318Prepaid expenses and other current assets

    215,742280,950Total current assets

    1,811,7382,046,525Long-term assets

    7,312,8857,439,674Total assets

    $
    9,124,623
    $
    9,486,199
    LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Current portion of long-term debt

    $
    440,706$
    347,749Accounts payable, accrued expenses and other current liabilities

    1,038,406798,636Total current liabilities

    1,479,1121,146,385Long-term debt

    2,298,4732,727,624Other long-term liabilities

    793,7681,174,161Stockholders' equity

    4,553,2704,438,029Total liabilities and stockholders' equity

    $
    9,124,623
    $
    9,486,199

    '/>"/>

    SOURCE Life Technologies Corporation
    Copyright©2010 PR Newswire.
    All rights reserved


    Related biology technology :

    1. Synterra Energy Merges Key Technologies to Commercialize Next Generation Integrated Bio-refinery
    2. Life Technologies Introduces First and Only USDA-Approved Real-Time PCR Test to Detect Swine Influenza Virus
    3. Life Technologies Launches New Distribution Center in India
    4. Biobanking: Technologies and Global Markets
    5. Stem Cell Technologies: World Market Outlook 2011-2021
    6. Wound Management Technologies Webcasting Live from OneMedForum NY Biotech Conference on Thursday, June 23 at 10 am EDT
    7. CMHC/MIS Electronic Health Record Solution from Netsmart Technologies Attains Complete ARRA Certification
    8. Genetic Technologies Launches BREVAGen™ Breast Cancer Risk Test in US
    9. Statement by Ronald L. Stotish, Ph.D., President and CEO of AquaBounty Technologies
    10. Life Technologies Launches Highly Efficient Stem Cell Reprogramming Technology
    11. Palatin Technologies, Inc. Announces Presentation and Publication on Validation of Scale for Subjective Male Sexual Arousal
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/9/2016)... ... 09, 2016 , ... The American Academy of Thermology (AAT) has ... 2016 AAT Member Certification Qualification Course for Technicians via a two part webinar on ... include a detailed review of hardware, software, and camera setup/operations, aligns with the in-person ...
    (Date:2/9/2016)... HOUSTON , Feb. 9, 2016 /PRNewswire/ ... virus-driven immunotherapies for cancer, announced that its ... the European Commission as an orphan medicinal ... the deadliest form of glioma, strikes approximately ... and EU. http://photos.prnewswire.com/prnh/20160208/330986LOGO ...
    (Date:2/9/2016)... 2016 Three-Year Initiative Supports Next Generation ... Part in Life-Changing Camp Experiences ... positively affect the lives of children born with rare diseases, as ... SHPG ) is announcing a new initiative designed to positively affect ... the future of rare disease care. --> To mark ...
    (Date:2/8/2016)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") ... clean technology companies in the TSX Venture 50 TM . ... on the TSX Venture Exchange, in each of five major ... & life sciences, diversified industries and technology – based ... on investment, market cap growth, trading volume and analyst coverage. ...
    Breaking Biology Technology:
    (Date:2/3/2016)... , Feb. 3, 2016 ... the addition of the "Emotion Detection ... Machine Learning, and Others), Software Tools (Facial ... Areas, End Users,and Regions - Global forecast ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has ...
    (Date:2/2/2016)... , Feb. 2, 2016 This ... the bioinformatic market by reviewing the recent advances ... tools that drive the field forward. Includes forecast ... Identify the challenges and opportunities that exist ... and software solution developers, as well as IT ...
    (Date:2/2/2016)... , Feb. 2, 2016 Technology Enhancements Accelerate ... an analysis of the digital and computed radiography markets ... , and Indonesia (TIM). ... and market size, as well as regional market drivers ... and discusses market penetration and market attractiveness, both for ...
    Breaking Biology News(10 mins):